Skip to content

Omeros OMER Royalty Obligation Noncurrent

Royalty Obligation Noncurrent at other companies

uniQure logo
uniQureQURE
$482.33M+8.0%
Ardelyx logo
ArdelyxARDX
$6.5M+1.4%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$407.18M-12.7%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$40.32M+17.5%
Geron logo
GeronGERN
$110.38M0.0%
Abercrombie & Fitch logo
Abercrombie & FitchANF
$34.31M+3.8%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$765.73M+307%
P/S8.5×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept omer:RoyaltyObligationNoncurrent.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's royalty obligation noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's royalty obligation noncurrent?
Omeros (OMER) reported royalty obligation noncurrent of $141.93M in Q1 2026.
How has Omeros's royalty obligation noncurrent changed year-over-year?
Omeros's royalty obligation noncurrent decreased by 25.3% year-over-year, from $190.09M to $141.93M.
What is the long-term trend for Omeros's royalty obligation noncurrent?
Over 2 years (2023 to 2025), Omeros's royalty obligation noncurrent has grown at a 12.4% compound annual growth rate (CAGR), from $116.55M to $147.32M.
What does royalty obligation noncurrent mean?
This represents the long-term portion of royalty payment obligations to third parties that are due beyond one year. It reflects the company's ongoing commitment to share future product revenues with partners or licensors over an extended period. This metric is used to assess the long-term impact of licensing agreements on future profitability.